Physician profile
Jonathan D Kloss
NPI 1134118565
$4,682.68
in general payments reported to CMS, 2019-2025
52 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,803 · 2020: $947 · 2021: $1,092 · 2022: $772 · 2024: $69.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $69.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $69.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $576.94 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $381.11 | 2019-2022 | |
| Genzyme Corporation | $271.69 | 2019-2022 | |
| Genentech USA, INC. | $261.87 | 2019-2022 | |
| Pfizer INC. | $238.90 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $189.11 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $183.10 | 2019-2022 | |
| Lilly USA, LLC | $182.83 | 2019-2022 | |
| Puma Biotechnology, INC. | $167.04 | 2019-2022 | |
| Incyte Corporation | $165.91 | 2019-2024 | Jakafi |
| Epizyme, INC. | $165.71 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $161.16 | 2020-2022 | |
| Acrotech Biopharma INC. | $153.80 | 2021-2022 | |
| Astellas Pharma US INC | $143.59 | 2019-2022 | |
| Celgene Corporation | $129.09 | 2019-2024 | Pomalyst |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Kloss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.